整合 PD-1/CD28 转换与亲环素 A 的三顺反子 CLDN18.2 CAR-T 细胞开发及其增强实体瘤免疫治疗的研究
Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy.
46.3分
★★★☆☆
站内排序·非疗效
ALL SOURCES
Development of tri-cistronic CLDN18.2 CAR-T cells incorporating PD-1/CD28 switch and cyclophilin A for enhanced solid tumor immunotherapy.
Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。